Academic Journal

XRCC2 driven homologous recombination subtypes and therapeutic targeting in lung adenocarcinoma metastasis

التفاصيل البيبلوغرافية
العنوان: XRCC2 driven homologous recombination subtypes and therapeutic targeting in lung adenocarcinoma metastasis
المؤلفون: Han Gong, Peihe Zhang, Qiang Liu, Yuxuan Tian, Fuxin Chen, Siyi Qian, Chaofeng Tu, Yueqiu Tan, Xingming Hu, Bin Zhang
المصدر: npj Precision Oncology, Vol 8, Iss 1, Pp 1-14 (2024)
بيانات النشر: Nature Portfolio, 2024.
سنة النشر: 2024
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Abstract Lung adenocarcinoma (LUAD) is a leading cause of cancer mortality, with many patients facing poor prognosis, particularly those with metastatic or drug-resistant tumors. Homologous recombination genes (HRGs) are crucial in tumor progression and therapy resistance, but their clinical significance in LUAD is not well understood. In this study, we systematically characterize key HRGs in LUAD patients, identifying two distinct HR subtypes associated with different outcomes and biological functions. We establish a 5-gene scoring system (XRCC2, RAD51, BRCA1, FANCA, and CHEK1) that reliably predicts patient outcomes and immunotherapy responses in LUAD. Bioinformatics analysis and clinical validation highlight XRCC2 as a crucial biomarker in LUAD. Functional investigations through in vivo and in vitro experiments reveal the role of XRCC2 in promoting lung cancer migration and invasion. Mechanistically, XRCC2 stabilizes vimentin (VIM) protein expression through deubiquitylation. We predict c-MYC as a potential regulator of XRCC2 and demonstrate that inhibiting c-MYC with compound 10058-F4 reduces XRCC2 and VIM expression. Preclinical studies show the synergistic inhibition of metastasis in vivo when combining 10058-F4 with doxorubicin (Dox). Our findings present a potential personalized predictive tool for LUAD prognosis, identifying XRCC2 as a critical biomarker. The c-Myc-XRCC2-VIM axis emerges as a promising therapeutic target for overcoming lung metastasis. This study provides valuable insights into LUAD, proposing a prognostic tool for further clinical validation and unveiling a potential therapeutic strategy for combating lung metastasis by targeting c-Myc-XRCC2-VIM.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2397-768X
Relation: https://doaj.org/toc/2397-768X
DOI: 10.1038/s41698-024-00658-y
URL الوصول: https://doaj.org/article/aab5b71e8c774ac4835276ea060d0099
رقم الانضمام: edsdoj.b5b71e8c774ac4835276ea060d0099
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:2397768X
DOI:10.1038/s41698-024-00658-y